#Biopsies

Paul Bröckelmann

BroeckelmannPJ

Excited to share updated data of the GHSG phase II NIVAHL trial investigating sequential and concomitant Nivo + AVD 1st-line treatment in early-stage unfavorable #Hodgkin lymphoma at @ASH_hematology: https://bit.ly/2LgW0g5

𝚃𝚛𝚞𝚗𝚐 𝙿𝚑𝚊𝚗 🇨🇦

TrungTPhan

Just read Ark Invest's Big Ideas 2021 report.A tweet for each idea (big numbers coming) 1/ Deep learning to create $30T of market value by 2037• Automated code writing •

Bill Foster

billfoster21

DermTech: Game-Changing Skin Cancer Detection DermTech is a healthcare disruptor that’s created a new product to detect skin cancer that is cheaper, more accurate, and less invasive than the current

𝙴𝚕𝚜𝚊𝚎𝚜𝚜𝚎𝚛 𝙳𝚎𝚛𝚖𝚊𝚝𝚘𝚙𝚘𝚞𝚕𝚘𝚜

dermatopoulos

Excellente prise de position, brillamment discutée, contre le dépistage systématique du mélanome dans la population générale et pour plus de discernement dans la pratique d’exérèses de lésions « suspectes » et l’interpréta

Amy Proal, PhD

microbeminded2

This is an incredibly important preprint to inform #LongCovid. Among many analyses, the team recruited 4 patients w/ prolonged + recurrent olfactory function loss after #COVID-19 (time from first COVID-19

José C. Marín

jocamaga1974

Duodenal adenomas (picture) are a common problem in the upper GI of the patients with familial adenomatous polyposis (FAP)However, adenomas and gastric cancer are a matter of increasing concernA thread

🦎 Alex 🚫

AlexAlicit

No. We aren't a third sex and stop using us to push your narrative. I'm tired of repeating myself on the manner but if you actually did your research on

Ryan Reeves

investing_city

Genomics Thread #5We've already laid the groundwork for understanding DNA, and some parts of the sequencing value chain but now let's talk about genetic testing... 1/ You can think of

Maxx Chatsko

7MaxxChatsko

1/ Quick take: $DMTKIndustry: Genetic diagnosticsMarket cap: $250mPlatform: Less invasive and lower-cost detection of melanoma from suspicious moles and skin lesions. A lot of chatter about this being a hidden gem

Nik Joshi

Joshilabyale

I’m excited to announce that our paper showing how tumor draining lymph nodes contain a long-term, stable reservoir of anti-tumor CD8 T cells is now online at @biorxiv. This is

Daniel Catenacci

DocCatenacci

#Tweetorial1️Only ~40-60% of GEA pts receive 2L Rx in the USA, & the treatment landscape is fragmented. https://pubmed.ncbi.nlm.nih.gov/25792290/ https://pubmed.ncbi.nlm.nih.gov/31056940/ @TumorBoardTues #TumorBoardTuesday

Compound Novice

CompoundNovice

$DMTK is a medtech co set to grow over 100% this yearHere's a quick pitch including concerns about gross margin, and why it's up 26% today 1/ What they do$DMTK

Ryan Reeves

investing_city

Genomics Thread #3Let's move onto some companies!Up first is Pacific BioSciences... 1/ When talking about genomics, the first company that comes to mind for people is likely Illumina. They really

Simon Barnett

sbarnettARK

Let's discuss a key aspect of vertical integration for diagnostics companies involved in #oncology testing:Synthetic Biology (#SynBio) We think maximum operating leverage will accrue to those companies who have bought,

Luiza Moore

luiza_moore

After many years and a real journey, we are excited to share our preprint on mutations in human cells!We studied multiple samples from the same individuals to explore mutational landscapes

Dave Feldman

DaveKeto

1/ #ReadingThreadThis paper by @zinocker, @kariannesve, @simondankel is proving an interesting read. Before I get too much further, I'm going to turn it into a "reading thread" and post some

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.